These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6127494)

  • 1. On-off syndrome in Parkinson's disease and intravenous levodopa.
    Lancet; 1982 Oct; 2(8305):992-3. PubMed ID: 6127494
    [No Abstract]   [Full Text] [Related]  

  • 2. On/off syndrome in Parkinson's disease and intravenous levodopa.
    Clough CG
    Lancet; 1982 Oct; 2(8301):765. PubMed ID: 6125830
    [No Abstract]   [Full Text] [Related]  

  • 3. [On-off phenomena in Parkinson's disease. Continuous dopaminergic stimulation].
    Stocchi F; Ruggieri S; Baronti F; Bellantuono P; Brughita G; Antonini A; Bravi D; Agnoli A
    Clin Ter; 1987 Jul; 122(2):83-8. PubMed ID: 2973904
    [No Abstract]   [Full Text] [Related]  

  • 4. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease.
    Sage JI; McHale DM; Sonsalla P; Vitagliano D; Heikkila RE
    Neurology; 1989 Jul; 39(7):888-91. PubMed ID: 2472582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Chase TN
    Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine and memory function in Parkinson's disease.
    Mohr E; Fabbrini G; Williams J; Schlegel J; Cox C; Fedio P; Chase TN
    Mov Disord; 1989; 4(2):113-20. PubMed ID: 2543918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease].
    Baronti F; Ruggieri S; Mouradian MM; Bonamartini A; Bocciarelli P; De Pandis MF; Chase TN; Agnoli A
    Riv Neurol; 1991; 61(6):210-4. PubMed ID: 1813972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
    Nyholm D
    Expert Rev Neurother; 2006 Oct; 6(10):1403-11. PubMed ID: 17078781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
    Antonini A; Mancini F; Canesi M; Zangaglia R; Isaias IU; Manfredi L; Pacchetti C; Zibetti M; Natuzzi F; Lopiano L; Nappi G; Pezzoli G
    Neurodegener Dis; 2008; 5(3-4):244-6. PubMed ID: 18322402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease. The L-dopa era.
    Yahr MD
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract]   [Full Text] [Related]  

  • 11. Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Clin Neuropharmacol; 1986; 9(2):165-81. PubMed ID: 3708602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa for Parkinson's disease.
    Devos D; Moreau C; Destée A
    N Engl J Med; 2009 Feb; 360(9):935-6; author reply 936. PubMed ID: 19246370
    [No Abstract]   [Full Text] [Related]  

  • 13. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease.
    Wooten GF
    Ann Neurol; 1988 Sep; 24(3):363-5. PubMed ID: 3067652
    [No Abstract]   [Full Text] [Related]  

  • 14. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
    Nutt JG; Woodward WR; Hammerstad JP; Carter JH; Anderson JL
    N Engl J Med; 1984 Feb; 310(8):483-8. PubMed ID: 6694694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.
    Cedarbaum JM; Silvestri M; Kutt H
    Neurology; 1990 Jun; 40(6):995-7. PubMed ID: 2345621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy of Parkinson disease].
    Dietrichs E
    Tidsskr Nor Laegeforen; 1992 Oct; 112(24):3106-9. PubMed ID: 1471089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Continuous dopaminergic stimulation in Parkinson disease].
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Pastor MA; Artieda J; Martínez-Lage JM
    Neurologia; 1987; 2(5):227-34. PubMed ID: 2908545
    [No Abstract]   [Full Text] [Related]  

  • 19. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
    Agid Y; Barroche G; Bonnet AM; Javoy-Agid F; Kato G; Lhermitte F; Pollak P; Signoret JL
    Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.